Echelon Wealth Partners analyst Stefan Quenneville reiterated a Buy rating on Valeo Pharma (VPHIF – Research Report) today and set a price target of C$1.00. The company’s shares opened today at $0.28.
According to TipRanks, Quenneville is an analyst with an average return of -11.2% and a 29.17% success rate.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Valeo Pharma with a $0.75 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $0.67 and a one-year low of $0.15. Currently, Valeo Pharma has an average volume of 3,323.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing or similar arrangements. Its current markets its product Synacthen Depot which is a synthetic ACTH product that is used in conditions where the production of natural cortisol and other hormones is desired.
Read More on VPHIF:
